Iodocyanopindolol: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 27: | Line 27: | ||
{{stub}} | {{stub}} | ||
<gallery caption="Iodocyanopindolol"> | |||
File:3-Iodocyanopindolol.svg|Chemical structure of 3-Iodocyanopindolol | |||
File:Iodocyanopindolol-3D-spacefill.png|3D space-filling model of Iodocyanopindolol | |||
</gallery> | |||
Latest revision as of 01:01, 18 February 2025
Iodocyanopindolol is a radioligand that is commonly used in medical research. It is a non-selective beta blocker that has been labeled with iodine-125, a radioisotope of iodine. This allows it to be used in radioligand binding assays to study the beta adrenergic receptor.
History[edit]
Iodocyanopindolol was first synthesized in the late 20th century as part of efforts to develop new tools for studying the beta adrenergic receptor. Its high affinity for this receptor and its ability to be labeled with iodine-125 made it an ideal candidate for use in radioligand binding assays.
Use in Research[edit]
In research settings, iodocyanopindolol is used to study the beta adrenergic receptor. It is particularly useful for this purpose because it is a non-selective beta blocker, meaning it can bind to all subtypes of the beta adrenergic receptor. This allows researchers to study the overall function of these receptors, rather than focusing on a specific subtype.
Iodocyanopindolol is also used in radioligand binding assays, a type of experiment that allows researchers to measure the concentration of specific types of receptors in a sample. By labeling iodocyanopindolol with iodine-125, researchers can track the movement of the ligand and determine the concentration of beta adrenergic receptors in the sample.
Pharmacology[edit]
As a non-selective beta blocker, iodocyanopindolol can bind to all subtypes of the beta adrenergic receptor. This means it can inhibit the action of epinephrine and norepinephrine, two hormones that activate these receptors. However, because it is typically used in research rather than in clinical settings, the pharmacological effects of iodocyanopindolol in humans are not well-studied.
